Overture to continue
Wednesday, 11 June, 2008
Independent regulators have recommended the continuation of the Ovature ovarian cancer trial, being run by Novogen's (ASX: NRT) subsidiary Marshall Edwards.
The trial's Independent Data Monitoring Committee (IDMC) recommended the continuation of the phase III trial of the orally administered investigational drug phenoxodiol, a chemosensitising agent, in women with advanced, refractory ovarian cancer.
The trial is being run to determine its safety and effectiveness when used in combination with carboplatin.
The trial has been approved by the US FDA under a special protocol assessment program. It is recruiting patients in clinical sites across the US, UK, Europe and Australia.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
